eISSN: 1643-3750


Get your full text copy in PDF

Primary sclerosing cholangitis in Ubiquitin treatment - a report of 3 cases

Irena Ciećko-Michalska, Józef Bogdał, Gabriel Turowski

Med Sci Monit 1997; 3(2): CS238-241

ID: 500719

Treatment of primary sclerosing cholangitis is a difficult and still not a fuly solved problem . Both monotherapy and combined pharmacological therapy have shown little effect on inhibiting the disease process and preventing complications. In 1994 attempts at applying ubiquitin biotherapy were made by using a thymus extract (TFX-Polfa) which proved to be a ubiquitin preparation, not only active in the immune system but also playing a significant role in regenerative and adjuvant processes. Methods: The study included 3 patients with primary sclerosing cholangitis who were given ubiquitins at a dose of 30 mg weekly for 3 months followed by 20 mg weekly for 6 months or longer. The patients were assessed biochemically and immunologically. Conclusions: Preliminary results of our study show a beneficial effect of ubiquitin biotherapy on the liver.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree